Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia January 8, 2026 4:30 PM EST
Company Participants
Scott Smith – CFO, Executive VP & Member of Executive Board
Jan Mikkelsen – President, CEO, Member of Executive Board & Executive Director
Aimee Shu – Executive VP & Chief Medical Officer
Conference Call Participants
Tazeen Ahmad – BofA Securities, Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Gabriella Garr – TD Cowen, Research Division
Maxwell Skor – Morgan Stanley, Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Yun Zhong – Wedbush Securities Inc., Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Luca Issi – RBC Capital Markets, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Presentation
Operator
Thank you for standing by, and welcome to Ascendis Pharma’s Phase II COACH trial top line week 52 data Call. [Operator Instructions]
I would now like to hand the call over to Scott Smith, Ascendis Pharma’s CFO. Please go ahead.
Scott Smith
CFO, Executive VP & Member of Executive Board
Thank you so much, operator, and thank you, everyone, for joining us on today’s call. Joining me are Jan Moller Mikkelsen, President and Chief Executive Officer; and Aimee Shu, Executive Vice President of Endocrine and Rare Disease Medical Sciences and Chief Medical Officer.
Before we begin, I would like to remind you that this presentation will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our continued development of TransCon CNP and TransCon Growth Hormone combination treatment, our pipeline candidates and expectations with
Read the full article here